Peptonic Medical AB (publ) today announced the launch of two new products on the home market in Sweden: VagiVital Menopause FSH Test and VagiVital Urinary Tract Infection Self Test, both of which represent significant milestones in the work to build the market’s most complete offer that diagnoses, treats and prevents women’s intimate health through clinically proven self-care products.
“We are now taking further important steps in the creation of the market’s most complete offering in women’s intimate health,” said Fanny Falkman Grinndal, Nordic Business Manager at Peptonic Medical.
VagiVital Urinary Tract Infection Self Test is a self-test that offers fast and reliable diagnosis of urinary tract infections, with a clinically proven accuracy of 99%. The reason for the high precision is that the test measures four parameters – leukocytes, blood, protein, and nitrite – while most existing tests only measure two or three. This user-friendly test provides results in just 2 minutes.
Urinary tract infection is a distressing and common condition that affects 50-60% of all women of all ages with many women experiencing recurrent infections, making the VagiVital Urinary Tract Infection Self Test a valuable product for many women.
VagiVital Menopause FSH Test is a self-test designed to detect early signs of perimenopause and menopause, with a clinically proven accuracy of 94%. The test gives a clear indication of whether a woman is in menopause, and it delivers results in just 5 minutes.
Menopause marks an important time of transition in a woman’s life, and perimenopause can begin as early as the age of 35 with a variety of diffuse symptoms. The VagiVital Menopause FSH test gives women a better understanding of the symptoms they are experiencing and facilitates the decision on possible next steps.
These products represent valuable complements to the company’s existing product portfolio and offer an important addition to existing and potential customers in Sweden, Norway, Denmark, and Europe. The launch is expected to have a positive impact on sales of Peptonic Medical’s existing product range. By improving the availability of diagnostic self-tests at home, the company expects continued increased interest and engagement, which drives overall growth for VagiVital’s product portfolio, which is already growing very rapidly in the domestic market today.
”Through two new self tests, we strengthen our position as a leader in women’s intimate health, while at the same time giving women the opportunity to monitor their health in a proactive and independent way with clinically proven self-care products,” said Fanny Falkman-Grinndal.
VagiVital FSH Menopause Self Test and VagiVital UTI Self Test are now available for purchase directly from Peptonic Medical’s official online store: www.vagivital.se.
For further information, please contact:
Fanny Falkman Grinndal, Business Manager Nordics, Peptonic Medical (media)
Phone: +46 70-196 17 97
Email: fanny.falkman-grinndal@peptonicmedical.se
Erik Sundquist, CEO, Peptonic Medical (investor relations)
Phone: +46 722 49 90 43
Email: erik.sundquist@peptonicmedical.se
About PEPTONIC Medical AB
Peptonic Medical AB is an innovative Swedish biomedical company engaged in research, development, and sales of unique medical treatments in the field of women’s intimate health. Under the brand VagiVital®, the product portfolio encompasses treatments for various conditions such as vaginal atrophy, bacterial vaginosis, and urinary tract infections. These clinically tested products address the growing demand for intimate self-care within the business concept of Diagnose, Treat, Prevent. Sweden serves as the reference market to facilitate geographic expansion in collaboration with local distributors. The United States is the largest market in terms of sales. The company is headquartered in Stockholm, Sweden, with a sales office in New York, NY, and an R&D unit in Caesarea, Israel. Peptonic Medical also has a wholly owned subsidiary, Lune Oy, in Finland, focusing on sustainable period products sold under the Lunette®️ brand (www.lunette.com). The company’s shares have been listed on www.spotlightstockmarket.com since 2014.
